Foamix, a specialty pharmaceutical company, and LEO Pharma have entered into a settlement and license agreement with an affiliate of Teva to resolve pending patent litigation involving Finacea Foam.

(RTTNews) - Foamix Pharmaceuticals Ltd. (FOMX) said Tuesday that, together with LEO Pharma, it has settled the Hatch-Waxman litigation with Perrigo, relating to Finacea Foam. Terms of the settlement ...

Bayer HealthCare announced that the Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam 15% for the topical treatment of inflammatory papules and pustules of mild to moderate ...

BRIDGEWATER, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing ...

Azelaic acid 15%; foam; contains propylene glycol. Monitor patients with dark complexions for hypopigmentation. Discontinue if sensitivity or severe irritation develops. Avoid eyes, mouth, other ...

DUBLIN, Feb. 20, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug ...

HealthDay News — The FDA has approved a new prescription treatment for rosacea. Finacea (azelaic acid) Foam, 15%, has been approved for the topical treatment of mild to moderate rosacea, according to ...

The first commercial product developed for the American market by Israeli biotech start-up Foamix has received FDA approval, the company announced last week. Finacea Foam, a 15% solution of azelaic ...

* FDA approves Bayer's Finacea (azelaic acid) foam for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea ...